Trial Profile
A Similar Phase I Study on the Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With Advanced NSCLC Treated With Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) Before and After Process Change
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Oct 2020
Price :
$35
*
At a glance
- Drugs Toripalimab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Shanghai Junshi Biosciences
- 28 Sep 2020 Status changed from active, no longer recruiting to completed.
- 07 Mar 2019 Planned End Date changed from 19 Dec 2018 to 1 Dec 2019.
- 04 Sep 2018 Planned End Date changed from 30 Jul 2018 to 19 Dec 2018.